10x Genomics is creating revolutionary DNA sequencing technology to help researchers better identify subtle variations that are overlooked by technologies that shred biological samples into tiny fragments before sequencing the short stretches and using computers to assembling them into a genome.
Benchling is the modern software platform purpose-built for life science R&D. Hundreds of thousands of scientists using cutting-edge techniques like CRISPR, CAR-T immunotherapy, and genetic engineering depend on our suite of cloud applications to design DNA, collaborate on experiments, manage research workflows, and make critical R&D decisions. Benchling is powering breakthrough research on biotherapeutics, biofuels, and biomaterials at leading life science companies and the world's most renowned academic labs. The company is focusing on life science collaboration, both private and public, through creating cloud-based software tools for digital DNA sequence editing, designing and running experiments, analyzing data, and sharing research. Benchling software includes an electronic lab notebook that allows researchers to document their experiments. It was founded in 2012 and is headquartered in San Francisco, California, United States.
BenchSci's vision is to bring medicine to patients 50% faster by 2025. The company empowers scientists with the world’s most advanced biomedical artificial intelligence to run more successful experiments. Backed by F-Prime, Gradient Ventures (Google’s AI fund), and Inovia Capital, BenchSci's proprietary technology accelerates science at 15 top 20 pharmaceutical companies and over 4,300 leading research centers worldwide. BenchSci is a CIX Top 10 Growth company, certified Great Place to Work, and top-ranked company on Glassdoor.
Biofourmis is a biotechnology company that augments personalized care and therapies using digital therapeutics. The company discovers, develops, and delivers clinically validated software-based therapeutics to enable better outcomes for patients. These solutions include advanced tools for clinicians to deliver personalized care and cost-effective solutions for payers. Biofourmis was founded in 2015 and headquartered in Boston, Massachusetts.
Biognosys believe that the decoding of the proteome will impact the life sciences more than the genome revolution a decade ago, and they strive to be the company that enables the routine analysis of proteomes in each research and clinical laboratory worldwide.Biognosys offers a unique next-generation solution for precise quantification of large proteomes in biological samples. Their technology provides unprecedented depth and quality of protein expression data for more effective biomarker and drug-target discovery and validation. Biognosys is a spin-off from the leading proteomics lab of Prof. Ruedi Aebersold, ETH Zurich.
Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat untraceable cancers. It aims to be the biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.
CARsgen is a leading clinical-stage immunotherapy company focused on the development of new chimeric antigen receptor T (CAR-T) cell therapeutics for liver, lung, stomach and brain cancers. The company has partnership with Shanghai Cancer Institute and Shanghai Renji Hospital. The company is leading the first tier of CAR-T development, by completing World’s first hepatocellular carcinoma (HCC) and China’s exclusive glioblastoma multiforme (GBM) dose ascending injection tests. Funded by leading venture capital firm BVCF, CARsgen is well-positioned to bring a novel cancer therapeutics to the market in China and worldwide.
Cibus’ breeding technology works without integrating foreign genetic material, thus the resulting organisms are non-transgenic (non-GM). The Company has developed and patented advanced breeding technologies that enable precise, stable, predictable changes to be made in plants and other organisms without integrating foreign genetic material. Cibus has launched its first crop, SU Canola, in North America and expects to develop non-transgenic traits in every major crop.
Complete Genomics' high quality, affordable DNA sequencing enables commercial-scale research of the genetic mechanisms underlying drug responses and complex diseases. Complete Genomics combines innovative technology with a disruptive market approach that will revolutionize DNA sequencing.
Congenica is a biotechnology company that provides a diagnostic decision support platform. They have translated this research into the gold standard clinical genomic analytics platform, Sapientia, providing integration of human DNA sequences with deep clinical phenotyping, enabling clinicians to provide an actionable interpretation of genetic disease for patients. It was founded in 2013 and headquartered in Cambridge, Cambridgeshire.
